Vaccines

PLATINUM COMPLEXES ABSTENTION ANTI-CANCER DRUG.

DRUG WITH RETARDED RELEASE.

SYNTHETIC PEPTIDE AND THESE CONTAINING PHARMACEUTICAL COMPOSITIONS

PLATINUM-ANTI-TUMOR IMMUNOGLOBULIN COMPLEXES

SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONS

PHARMACEUTICAL COMPOSITIONS COMPRISING SYNTHETIC PEPTIDE COPOLYMER FOR PREVENTION OF GVHD

Pharmaceutical compositions comprising as active ingredient a synthetic random copolymer of average molecular weight of about 4,000-12,000, preferably 6,0008,000, said copolymer consisting of glutamic acid (Glu), lysine (Lys), alanine (Ala) and tyrosine (Tyr) residues in a relative molar ratio of 1.4-2.1 parts of Glu to 3.2-5.0 parts of Lys to 4.0-6.6 parts of Ala to 1.0 parts of Tyr (herein GLAT copolymers), can be used in a method for prevention and treatment of graft-versus-host disease in patients in the course of bone marrow and organ transplantation.

COPOLYMER-1 IMPROVEMENTS IN COMPOSITIONS OF COPOLYMERS

The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

TREATMENT OF MULTIPLE SCLEROSIS THROUGH INGESTION OR INHALATION OF COPOLYMER-1

The present invention relates to the treatment of multiple sclerosis by ingestion or inhalation of copolymer-1 and pharmaceutical compositions useful for such treatment.

SYNTHETIC PEPTIDE FOR THE TREATMENT OF MYASTHENIA GRAVE

Synthetic peptides for the treatment of myasthenia gravis

Peptides having at least nine amino acid residues each including an amino acid sequence which corresponds to position p200-208 or p262-266 of the human acetylcholine receptor (alpha)-subunit, but differing therefrom by one or more amino acid substitutions, are disclosed. These peptides inhibit the proliferative response of human peripheral blood lymphocytes to the myasthogenic peptides p195-212 and p259-271 and are suitable for treatment of subjects afflicted with myasthenia gravis.

Pharmaceutical compositions comprising synthetic peptide cop olymer for prevention of gvhd

Pharmaceutical compositions comprising as active ingredient a synthetic random copolymer of average molecular weight of about 4,000-12,000, preferably 6,000-8,000, said copolymer consisting of glutamic acid (Glu), lysine (Lys), alanine (Ala) and tyrosine (Tyr) residues in a relative molar ratio of 1.4-2.1 parts of Glu to 3.2-4.4 parts of Lys to 4.0-6.0 parts of Ala to 1.0 parts of Tyr (herein GLAT copolymers), can be used in a method for prevention and treatment of graft-versus-host disease in patients in the course of bone marrow and organ transplantation.

METHODS AND COMPOSITIONS FOR CANCER THERAPY AND FOR PROGNOSTICATING RESPONSES TO CANCER THERAPY

A method for determining the efficacy of a therapeutic agent, in vitro, for a cancer expressing or overexpressing an oncogene product is described. The method is particularly useful for determining the efficacy of therapeutic agents that have a binding affinity for cancer that express HER-2/neu. N24, N28 and N29 monoclonal antibodies are described which have been identified by this method. One or more of these antibodies can be used as a therapeutic agent in the treatment of breast, stomach, ovarian or salivary cancers.

Fraction of copolymer-1 and method prodaction of it, composition for the treatment of multiple sclerosis, farmaceutical composition, method for the t reatment of multiple sclerosis.

Synthetic peptides and pharmaceutical compositions comprisin g them

Copolymer-1 Improvements in Compositions of Copolymers

Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy

ANTIGEN BINDING DIMER BOUND TO DRUG

ABSTRACT OF THE DISCLOSURE Chemotherapeutic agents comprising an antigen binding dimer derived from an immunoglobulin covalently bound to drug are disclosed. The dimer and drug are bound, while preserving both the antibody activity of the dimer and the pharmacological activity of the drug.

SYNTHETIC PEPTIDES FOR THE TREATMENT OF MYASTHENIA GRAVIS

Peptides having at least nine amino acid residues each including an amino acid sequence which corresponds to position p200-208 or p262-266 of the human acetylcholine receptor .alpha.-subunit, but differing therefrom by one or more amino acid substitu- tions, are disclosed. These peptides inhibit the proliferative response of human peripheral blood lymphocytes to the myasthogenic peptides p195-212 and p259-271 and are suitable for treatment of subjects afflicted with myasthenia gravis.

ANTIBODY COMBINATIONS AND USE OF SAME FOR TREATING CANCER

A method of identifying a combination of antibodies with a combined improved anti-tumor activity is provided. The method comprising: (a) identifying binding epitopes of anti ErbB-2 antibodies; and (b) selecting a combination of at least two antibodies of the anti ErbB-2 antibodies exhibiting binding to different epitopes on the ErbB-2, at least one of the different epitopes being localized to a dimerization site of the ErbB-2, the combination of antibodies being with the combined improved anti-tumor activity. Also provided are novel antibody combinations uncovered according to the present teachings.

PENICILLINS

... 1,224,181. Enzyme derivatives. BEECHAM GROUP Ltd. 26 Feb., 1969 [29 Feb., 1968], No. 9778/68. Heading C3H. [Also in Division C2] A water-insoluble pronase derivative is prepared by adding a solution of pronase in citrate phosphate buffer to bromoacetyl cellulose, stirring and adding a drop of antifoam agent. The suspension is centrifuged and the precipitate suspended in bicarbonate buffer, recentrifuged and the precipitate suspended in 2-aminoethanol in bicarbonate buffer and finally centrifuged and washed with sodium chloride solution until the supernatant has no optical density at 280 mÁ. Water-insoluble materials prepared from pronase and carboxymethyl cellulose or carboxymethyl - " Sephadex " (Registered Trade Mark) are also referred to.

IMPROVEMENTS CONTAINING IN COMPOSITIONS OF KOPOLYMEREN KOPOLYMER-1

PHARMACEUTICAL COMPOSITIONS, THE SYNTHETIC PEPTIDCOPOLYMERISATE CONTAINING, FOR PREVENTING OF GVHD

METHODS AND COMPOSITIONS TO THE CANCER THERAPY AND TO PREDICTABLENESS THE REACTIONS TO THIS TREATMENT

TREATMENT OF THE MULTIPLE SCLEROSIS BY INCOME OF COPOLYMER-1

COPOLYMER-1 IMPROVEMENTS IN COMPOSITIONS OF COPOLYMERS

The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

TREATMENT OF MULTIPLE SCLEROSIS THROUGH INGESTION OR INHALATION OF COPOLYMER-1

The present invention relates to the treatment of multiple sclerosis by ingestion or inhalation of copolymer-1 and pharmaceutical compositions useful for such treatment. © KIPO & WIPO 2007 ...

VACCINES

Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1

Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD

Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd

Copolymer-1 improvements in compositions of copolymers

SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS

ABSTRACT OF THE INVENTION The present invention pertains to biodegradable sustain-ed release pharmaceutical compositions. The compositions can be formed into implant devices which may be used to treat a wide variety of diseases and conditions. The implants are especially useful in treating diseases such as periodontal disease which require prolonged drug release.

Copolymer-1 improvements on compositions of copolymers

The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Verfahren zur Herstellung gereinigter 6-Aminopenicillansaeure und Penicilline

Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD

Pharmaceutical compositions comprising as active ingredient a synthetic random copolymer of average molecular weight of about 4,000-12,000, preferably 6,000-8,000, said copolymer consisting of glutamic acid (Glu), lysine (Lys), alanine (Ala) and tyrosine (Tyr) residues in a relative molar ratio of 1.4-2.1 parts of Glu to 3.2-4.4 parts of Lys to 4.0-6.0 parts of Ala to 1.0 parts of Tyr (herein GLAT copolymers), can be used in a method for prevention and treatment of graft-versus-host disease in patients in the course of bone marrow and organ transplantation.

VACCINES FOR ORAL IMMUNIZATION AGAINST INFECTING AGENTS

The invention relates to conjugates of an antigenic material selected from the group of a toxin, or a fragment thereof, a toxoid and/or an adherence antigen derived from an infecting agent, wherein said antigenic material is covalently bound to a physiologically acceptable inert carrier, such as silica, chemically-modified silica, aluminium silicate, kaolin or latex. The conjugates are for use in vaccines for oral immunization against infecting agents, e.g., gastrointestinal microbial infections such as cholera,

SYNTHETISCHE PEPTIDE UND DIESE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN

Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides

COMPOSITIONS FOR TREATMENT OF MALIGNANT GROWTHS

Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1

SYNTHETIC PEPTIDES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

Synthetic peptides having at least fourteen amino acid residues each including two linked amino acid sequences which correspond to positions p200-208 and p262-266 of the human acetylcholine receptor .alpha.subunit, but differing therefrom by one or more amino acid substitutions in each of said positions, are disclosed. These peptides inhibit the proliferative response of human peripheral blood lymphocytes to the myasthenogenic peptides p195-212 and p259-271 and are suitable for treatment of subjects afflicted with myasthenia gravis.

PROTEOLYTIC PURIFICATION OF PENICILLIN AND DERIVATIVES

ANTI-CANCER DRUGS COMPRISING PLATINUM COMPLEXES

There are provided anti-tumor agents comprising as active ingredient platinum complexed directly or via dextranamine moieties to an anti-tumor immunoglobulin. These are prepared by reacting an anti-tumor immunoglobulin or such immunoglobulin coupled to a dextran-amine with a platinum salt. Immunoglobulins having a specific binding activity towards certain types of cancer cells can be used. Immunoglobulins specific for ovarian or testicular carcinoma or for renal adenocarcinoma complexed directly or via dextran-amine moieties with platinum are effective agents for the treatment of these malignancies.

METHODEN UND ZUSAMMENSETZUNGEN ZUR KREBSTHERAPIE UND ZUR VORHERSAGBARKEIT DER REAKTIONEN AUF DIESE BEHANDLUNG

Copolymer-1 improvements in compositions of copolymers

Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides

SYNTHETIC PEPTIDES FOR THE TREATMENT OF MYASTHENIA GRAVIS

Peptides having at least nine amino acid residues each including an amino acid sequence which corresponds to position p200-208 or p262-266 of the human acetylcholine receptor .alpha.-subunit, but differing therefrom by one or more amino acid substitutions, are disclosed. These peptides inhibit the proliferative response of human peripheral blood lymphocytes to the myasthogenic peptides p195-212 and p259-271 and are suitable for treatment of subjects afflicted with myasthenia gravis.

METHODS AND COMPOSITIONS FOR CANCER THERAPY AND FOR PROGNOSTICATING RESPONSES TO CANCER THERAPY

A method for determining the efficacy of a therapeutic agent, in vitro, for a cancer expressing or overexpressing an oncogene product is described. The method is particularly useful for determining the efficacy of therapeutic agents that have a binding affinity for cancer that express HER-2/neu. N24, N28 and N29 monoclonal antibodies are described which have been identified by this method. One or more of these antibodies can be used as a therapeutic agent in the treatment of breast, stomach, ovarian or salivary cancers.

Methods and Compositions for Cancer Therapy and for Prognosticating Responses to Cancer Therapy

THE USE OF COPOLYMER 1 AND RELATED PEPTIDES AND POLYPEPTIDES AND T CELLS TREATED THEREWITH FOR NEUROPROTECTIVE THERAPY

Methods are provided for treating injury to or disease of the central or peripheral nervous system. In one embodiment, treatment is effected by administering activated T cells that recognize an antigen of Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration within the nervous system. In another embodiment, treatment involves administering Cop 1 or a Cop 1- related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration in the nervous system, either the central nervous system or the peripheral nervous system. The activated T cells, which have been activated by the presence of Cop 1 or a Cop 1-related peptide or polypeptide, can be administered alone or in combination with Cop 1 or a Cop 1-related peptide or polypeptide. © KIPO & WIPO 2007 ...

METHODEN UND ZUSAMMENSETZUNGEN ZUR KREBSTHERAPIE UND ZUR VORHERSAGBARKEIT DER REAKTIONEN AUF DIESE BEHANDLUNG

ANTI-CANCER DRUGS COMPRISING PLATINUM COMPLEXES

Copolymer-1 improvements in compositions of copolymers

Copolymer-1 improvements in compositions of copolymers

TREATMENT OF MULTIPLE SCLEROSIS THROUGH INGESTION OR INHALATION OF COPOLYMER-1

The present invention relates to the treatment of multiple sclerosis by ingestion or inhalation of copolymer-1 and pharmaceutical compositions useful for such treatment.

SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONS

Copolymer-1 improvements in compositions of copolymers

CONJUGATES OF ANTI-CANCER DRUGS WITH ANTIBODIES

Pharmaceutical compositions are disclosed for the treatment of different types of tumors, the compositions being low molecular weight anti-cancer drugs bonded to antibodies selective or specific to the different tumor antigens. Methods of preparation for the compositions are also disclosed.

Copolymer-1 Improvements in Compositions of Copolymers

ANTI-TUMOR COMPOSITION

The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy

Verbeserungen in Zusammensetzungen von kopolymeren enthaltend Kopolymer-1

THERAPEUTICAL AGENTS

Aptamers, multimeric aptamers and uses thereof

Monomeric and multimeric aptamers are provided. Also provided are pharmaceutical compositions which comprise same and methods of using same.

Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD

Compositions and methods for treating and preventing host-versus-graft disease and graft-versus-host disease comprising as active ingredient random copolymers of amino acids comprising one amino acid from at least three of the following groups: (a) lysine and arginine; (b) glutamic acid and aspartic acid; (c) alanine and glycine; and (d) tyrosine and tryptophan; with the proviso that the random copolymer is not Copolymer 1 or D-Copolymer 1 when the disease being treated is graft-versus-host disease.

Method and compositions for cancer therapy and for prognosticating responses to cancer therapy

Synthetic peptides for the treatment of myasthenia gravis

Synthetic peptides and pharmaceutical compositions comprising them

PLATINUM-ANTI-TUMOR IMMUNOGLOBULIN COMPLEXES

METHODS OF IDENTIFYING COMBINATIONS OF ANTIBODIES WITH AN IMPROVED ANTI-TUMOR ACTIVITY AND COMPOSITIONS AND METHODS USING THE ANTIBODIES

A method of identifying a combination of antibodies with a combined improved anti tumor activity is provided. The method comprising identifying at least two anti RTK antibodies capable of inducing synergistic endocytosis of the RTK in a cell expressing the RTK, thereby identifying the combination of antibodies with the combined improved anti-tumor activity.

Antibody combinations and use of same for treating cancer

A method of identifying a combination of antibodies with a combined improved anti-tumor activity is provided. The method comprising: (a) identifying binding epitopes of anti ErbB-2 antibodies; and (b) selecting a combination of at least two antibodies of the anti ErbB-2 antibodies exhibiting binding to different epitopes on the ErbB-2, at least one of the different epitopes being localized to a dimerization site of the ErbB-2, the combination of antibodies being with the combined improved anti-tumor activity. Also provided are novel antibody combinations uncovered according to the present teachings.

SYNTHETISCHE PEPTIDE UND DIESE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN

Bakteriophagen-Protein-Konjugate,deren Herstellung und Verwendung zum Nachweis und zur quantitativen Bestimmung von Proteinen

The use of copolymer 1 and related peptides and polypeptides and t cells treatedtherewith for neuroprotective therapy

Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD

Copolymer-1 improvements in compositions of copolymers

The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Copolymer-1 improvements in compositions of copolymers

The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

SYNTHETISCHE PEPTIDE FÜR DIE BEHANDLUNG VON MYASTHENIA GRAVIS

VERBESSERUNGEN IN ZUSAMMENSETZUNGEN VON KOPOLYMEREN ENTHALTEND KOPOLYMER-1

Treatment of autoimmune conditions with copolymer 1 and related copolymers

The present invention provides heteropolymer compositions and peptide compositions, and methods of making and using therapeutic compositions comprising amino acid heteropolymers for treatment of a subject for an autoimmune or an inflammatory disease, the heteropolymer compositions made by solid state synthesis. The invention also provides kits for assaying binding of a composition to a water-soluble MHC protein.

SYNTHETISCHE PEPTIDE FÜR DIE BEHANDLUNG VON MYASTHENIA GRAVIS

BEHANDLUNG DER MULTIPLEN SKLEROSE DURCH EINNAHME VON COPOLYMER-1

ARZNEIMITTEL MIT VERZOEGERTER FREISETZUNG.

MURAMYL PEPTIDES FIXED ON PEPTIDE POLYMERS AND MEDICAMENTS CONTAINING THEM

BEHANDLUNG DER MULTIPLEN SKLEROSE DURCH EINNAHME VON COPOLYMER-1

PHARMAZEUTISCHE ZUSAMMENSETZUNGEN, DIE SYNTHETISCHE PEPTIDCOPOLYMERISATE ENTHALTEN, ZUR VERHÜTUNG VON GVHD

VERBESSERUNGEN IN ZUSAMMENSETZUNGEN VON KOPOLYMEREN ENTHALTEND KOPOLYMER-1

VERWENDUNG VON COPOLYMER 1- UND VERWANDTEN PEPTIDEN SOWIE VON POLYPEPTIDEN UND DAMIT BEHANDELTEN T-ZELLEN ZUR NEUROPROTEKTIVEN THERAPIE

PHARMAZEUTISCHE ZUSAMMENSETZUNGEN, DIE SYNTHETISCHE PEPTIDCOPOLYMERISATE ENTHALTEN, ZUR VERHÜTUNG VON GVHD

Copolymer-1 improvements in compositions of copolymers

The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER

An article-of-manufacture is provided. The article-of-manufacture comprises a packaging material identified for treating cancer, packaging: (i) an anti-EGFR antibody comprising the CDR sequences of anti EGFR 565 (CNCM Deposit Number I-4262); and (ii) an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L431 (CNCM Deposit Number I-4115), anti ErbB-2 L26 (CNCM Deposit Number I-4113) or anti ErbB-2 N12 (CNCM Deposit Number I-4112), or (iii) an anti-EGFR antibody comprising the CDR sequences of anti EGFR 111 (CNCM Deposit Number I-4261); and (iv) an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L431 (CNCM Deposit Number I-4115). Also provided are pharmaceutical compositions and methods of using the above antibodies as well as other antibody combinations for the treatment of cancer.

VERWENDUNG VON COPOLYMER 1- UND VERWANDTEN PEPTIDEN SOWIE VON POLYPEPTIDEN UND DAMIT BEHANDELTEN T-ZELLEN ZUR NEUROPROTEKTIVEN THERAPIE

ARZNEIMITTEL MIT VERZOEGERTER FREISETZUNG.

IMPFSTOFF GEGEN CHOLERA UND GEGEN HITZE-LABILES E. COLI-TOXIN

Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy

Methods are provided for treating injury to or disease of the central or peripheral nervous system. In one embodiment, treatment is effected by administering activated T cells that recognize an antigen of Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration within the nervous system. In another embodiment, treatment involves administering Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration in the nervous system, either the central nervous system or the peripheral nervous system. The activated T cells, which have been activated by the presence of Cop 1 or a Cop 1-related peptide or polypeptide, can be administered alone or in combination with Cop 1 or a Cop 1-related peptide or polypeptide.

COPOLYMER-1 IMPROVEMENTS IN COMPOSITIONS OF COPOLYMERS

The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons. 116-. (canceled)17. A copolymer-1 composition comprising a mixture of copolymers of alanine , glutamic acid , lysine and tyrosine , in a molar ratio of approximately 6:2:5:1 , respectively , the copolymer species in the mixture being non-uniform with respect to molecular weight and sequence , which is synthesized by polymerization of suitably protected amino acid carboxyanhydrides , wherein less than 5% of the copolymers have a molecular weight above 40 kDa , and wherein the composition is suitable for treating multiple sclerosis.18. The copolymer-1 composition of claim 17 , wherein less than 2.5% of the copolymers have a molecular weight above 40 kDa.19. The copolymer-1 composition of claim 19 , wherein the mixture of copolymers is synthesized by polymerization of N-carboxyanhydrides of alanine claim 19 , tyrosine claim 19 , γ-benzyl glutamate and ε-N-trifluoroacetyllysine.20. The copolymer-1 composition of claim 19 , wherein less than 2.5% of the copolymers have a molecular weight above 40 kDa. This application is a continuation-in-part of U.S. Ser. No. 08/344,248, filed Nov. 23, 1994, which is a continuation of U.S. Ser. No. 08/248,037, filed May 24, 1994.Copolymer-1 is a synthetic polypeptide analog of myelin basic protein (MBP), which is a natural component of the myelin sheath. It has been suggested as a potential therapeutic agent for multiple sclerosis (Eur. J. Immunol. [1971] 1:242; and J. Neurol. Sci. [1977]31:433. All references cited herein are hereby incorporated by reference in their entirety. Interest in copolymer-1 as an immunotherapy for multiple sclerosis stems from observations first made in the 1950's that myelin components such as MBP prevent or arrest experimental autoimmune encephalomyelitis (EAE). EAE is a disease resembling multiple sclerosis that can be induced in ...

Antibody combinations and use of same for treating cancer

A method of identifying a combination of antibodies with a combined improved anti-tumor activity is provided. The method comprising: (a) identifying binding epitopes of anti ErbB-2 antibodies; and (b) selecting a combination of at least two antibodies of the anti ErbB-2 antibodies exhibiting binding to different epitopes on the ErbB-2, at least one of the different epitopes being localized to a dimerization site of the ErbB-2, the combination of antibodies being with the combined improved anti-tumor activity. Also provided are novel antibody combinations uncovered according to the present teachings.

Copolymer-1 improvements in compositions of copolymers

The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same

Hybridoma cell lines producing monoclonal antibodies specific to the human epidermal growth factor receptor are disclosed. The antibodies are capable of inhibiting the growth of human tumor cells expressing human epidermal growth factor receptors. Therapeutic uses of these monoclonal antibodies by themselves and in combination with anti-neoplastic agents are also disclosed.

TREATMENT OF AUTOIMMUNE CONDITIONS WITH COPOLYMER 1 AND RELATED COPOLYMERS

The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal. 1. A terpolymer consisting essentially of tyrosine , alanine and lysine randomly polymerized into a polypeptide.215.-. (canceled)16. A pharmaceutical composition for the treatment of an autoimmune disease , comprising a therapeutically effective amount of a terpolymer comprising three different amino acids randomly polymerized into a polypeptide , and a pharmaceutically acceptable carrier , wherein the three different amino acids are selected from the group of tyrosine , glutamic acid , alanine and lysine.1744.-. (canceled)45. A method for treating an autoimmune disease which comprises administering a therapeutically effective amount of a polypeptide consisting essentially of amino acids tyrosine , glutamic acid , alanine and lysine , wherein said autoimmune disease is not multiple sclerosis.46176.-. (canceled) The present application is a continuation of U.S. Ser. No. 12/231,292, filed Aug. 29, 2008 which is a continuation of U.S. Ser. No. 11/528,894, filed Sep. 27, 2006 which is a divisional 10 of U.S. ...

SYSTEMS AND METHODS FOR ANALYZING ONLINE SURVEYS AND SURVEY CREATORS

A system can include a question repository to store multiple sets of questions, each set of questions including questions that may have a superficial, semantic, or open-ended modifier portion. A survey management module can allow a user to select a set of questions from the question repository for an online survey. A benchmarking module can group questions by semantic modifier options and provide an analysis based on information about the survey-creator and other survey-creators. 1. A system , comprising:a question repository configured to store multiple sets of questions, each set of questions including questions that have a superficial modifier portion, a semantic modifier portion, an open-ended modifier portion, or a combination thereof;a survey management module configured to allow a user to select a set of questions from the question repository for an online survey, wherein the survey management module is further configured to provide superficial modifier, semantic modifier, and open-ended modifier options for each question having such modifier portions; anda benchmarking module configured to collect information about the survey-creator, group the questions by semantic modifier options, and provide an analysis based on the collected information and information about other survey-creators that created other surveys with a question having the same semantic modifier options.2. The system of claim 1 , further comprising a storage module configured to store results of the analysis.3. The system of claim 1 , further comprising a user interaction module configured to control a user interface that provides a visual representation of results of the analysis.4. The system of claim 3 , wherein the visual representation includes a bar graph portion claim 3 , a table portion claim 3 , or both.5. The system of claim 3 , wherein the user interaction module is further configured to allow a user to alter the analysis.6. The system of claim 5 , wherein the user interaction ...

COMBINATIONS OF EPIDERMAL GROWTH FACTOR RECEPTOR TARGETING ANTIBODIES FOR TREATING CANCER

A method of treating triple negative breast cancer in a subject comprising administering to the subject a therapeutically effective amount of a combination of at least two anti epidermal growth factor receptor (EGF-R) antibodies exhibiting binding to different epitopes on the EGF-R, thereby treating triple negative breast cancer. 1. A method of treating pancreatic cancer in a subject comprising administering to the subject a therapeutically effective amount of:(i) a first anti-EGFR antibody comprising the CDR sequences of anti EGFR 565 (CNCM Deposit Number I-4262), wherein said first anti-EGFR antibody binds the same EGFR epitope as said anti EGFR 565; and(ii) a second anti-EGFR antibody comprising the CDR sequences of C225/Cetuximab, wherein said second anti-EGFR antibody binds the same EGFR epitope as said C225/Cetuximab.2. The method of claim 1 , wherein said first anti-EGFR antibody and said second anti-EGFR antibody comprise full length antibodies.3. The method of claim 1 , wherein said method consists of administering said (i) and said (ii).4. The method of claim 1 , wherein said method further comprising administering to said subject a therapy selected from the group consisting of radiotherapy claim 1 , analgesics claim 1 , chemotherapy and hormonal therapy.5. The method of claim 4 , wherein said chemotherapy is anthracycline. This application is a Continuation of U.S. patent application Ser. No. 14/437,247 filed on Apr. 21, 2015, which is a National Phase of PCT Patent Application No. PCT/IL2013/050841 having International filing date of Oct. 17, 2013, which claims the benefit of priority under 35 USC §119(e) of U.S. Provisional Patent Application No. 61/717,733 filed on Oct. 24, 2012. The contents of the above applications are all incorporated by reference as if fully set forth herein in their entirety.This invention was made with government support under Contract No. CA072981 awarded by the NIH. The government has certain rights in the invention.The ...

Squat Exercising

The present disclosure comprises methods, apparatus, components, and techniques for performing a squat exercise. Embodiments of the present disclosure may assist the user to carry out a squat with proper form to reduce the risk of injury and increase effectiveness of the exercise. Embodiments of the present disclosure comprise a forward knee-arresting surface to restrict forward movement of the user's knees in order to keep the knees in line with the user's toes. Embodiments of the present disclosure further comprise lateral knee guides. A resistive force may be applied to the lateral knee guides to increase muscle exertion while carrying out the exercise. 1. An apparatus for carrying out a squat exercise comprising:an anterior knee guide;a lateral knee guide;a base;a vertical support for the anterior knee guide and the lateral knee guide, wherein the vertical support is connected by a lateral hinge to the base, the lateral hinge being adapted to provide lateral rotation of the vertical support.2. The apparatus of claim 1 , wherein the anterior knee guide comprises two plates.3. The apparatus of claim 1 , further comprising a resistance mechanism adapted to apply a resistive force to the lateral rotation of the vertical support.4. The apparatus of claim 3 , wherein the resistance mechanism comprises an elastic band.5. The apparatus of claim 3 , wherein the resistance mechanism comprises a flexible rod.6. The apparatus of claim 1 , wherein the base further comprises stance plates.7. A method of performing a squat by a user claim 1 , comprising:placing the user's knees at or proximate to a forward knee-arresting surface;lowering the user's body to a squat position while maintaining the user's knees at or proximate to the forward knee-arresting surface.8. The method of claim 7 , further comprising raising the user's body to an upright position.9. The method of claim 7 , further comprising:prior to bending the user's knees and waist, placing toes at a toe stop.10. The ...

Combinations of epidermal growth factor receptor targeting antibodies for treating cancer

A method of treating triple negative breast cancer in a subject comprising administering to the subject a therapeutically effective amount of a combination of at least two anti epidermal growth factor receptor (EGF-R) antibodies exhibiting binding to different epitopes on the EGF-R, thereby treating triple negative breast cancer.

Aptamers, multimeric aptamers and uses thereof

Monomeric and multimeric aptamers are provided. Also provided are pharmaceutical compositions which comprise same and methods of using same.

SYNTHETIC VACCINE AGAINST CHOLERA

VACCIN SYNTHETIQUE CONTRE LE CHOLERA ET LA TOXINE LABILE A LA CHALEUR DE E. COLI. IL COMPREND UN PRODUIT DE CONJUGAISON D'UN SUPPORT DE HAUT POIDS MOLECULAIRE ET D'UN POLYPEPTIDE SYNTHETIQUE CORRESPONDANT A UNE PARTIE DE LA SEQUENCE DE LA SOUS-UNITE B DE LA TOXINE NATURELLE DU CHOLERA. LES POLYPEPTIDES PREFERES CORRESPONDENT AUX SEQUENCES 45-64, 50-64 ET 8-20 DE CETTE SOUS-UNITE B, EVENTUELLEMENT LEGEREMENT MODIFIEES. SYNTHETIC VACCINE AGAINST CHOLERA AND HEAT LABILE TOXIN OF E. COLI. IT INCLUDES A CONJUGATION PRODUCT OF A HIGH MOLECULAR WEIGHT CARRIER AND SYNTHETIC POLYPEPTIDE CORRESPONDING TO PART OF THE B SUBUNIT SEQUENCE OF THE NATURAL CHOLERA TOXIN. THE PREFERRED POLYPEPTIDES CORRESPOND TO SEQUENCES 45-64, 50-64 AND 8-20 OF THIS SUB-UNIT B, POSSIBLY SLIGHTLY MODIFIED.

Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy

Procédé de détermination de l'efficacité d'un agent thérapeutique, in vitro, utilisé dans le traitement d'un cancer caractérisé par l'expression ou la surexpression d'un produit oncogène. Le procédé est notamment utile pour déterminer l'efficacité d'agents thérapeutiques présentant une affinité de liaison pour le cancer, exprimant HER-2/neu. L'invention concerne également les anticorps monoclonaux N24, N28 et N29 identifiés par ce procédé. On peut utiliser un ou plusieurs de ces anticorps comme agent thérapeutique dans le traitement des cancers du sein, de l'estomac, des ovaires ou des glandes salivaires. Method for determining the efficacy of a therapeutic agent, in vitro, used in the treatment of cancer characterized by the expression or overexpression of an oncogenic product. The method is particularly useful for determining the efficacy of therapeutic agents having a binding affinity for cancer, expressing HER-2 / neu. The invention also relates to the monoclonal antibodies N24, N28 and N29 identified by this method. One or more of these antibodies can be used as a therapeutic agent in the treatment of breast, stomach, ovarian or salivary gland cancers.

Anti-cancer drugs comprising platinum complexes

Copolymer-1 Enhancements Copolymer Preparations

Copolymer-1 improvements in compositions of copolymers

The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Combinations of epidermal growth factor receptor targeting antibodies for treating cancer

A method of treating triple negative breast cancer in a subject comprising administering to the subject a therapeutically effective amount of a combination of at least two anti epidermal growth factor receptor (EGF-R) antibodies exhibiting binding to different epitopes on the EGF-R, thereby treating triple negative breast cancer.

SYNTHETIC VACCINE AGAINST CHOLERA

Treatment of autoimmune conditions with copolymer 1 and related copolymers

The present invention is directed to polypeptides and peptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Morever, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides or peptides to the mammal.

Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd

Compositions and methods for treating and preventing host-versus-graft disease and graft-versus-host disease comprising as active ingredient random copolymers of amino acids comprising one amino acid from at least three of the following groups: (a) lysine and arginine; (b) glutamic acid and aspartic acid; (c) alanine and glycine; and (d) tyrosine and tryptophan; with the proviso that the random copolymer is not Copolymer 1 or D-Copolymer 1 when the disease being treated is graft-versus-host disease.

Method for prognosticating responses to cancer therapy

Treatment of autoimmune conditions with copolymer 1 and related copolymers

The present invention is directed to polypeptides and peptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Morever, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides or peptides to the mammal.

Copolymer-1: compositions of copolymers

Immunologic chemotherapeutic agents comprising antigen binding dimers covalently bound to drugs

Chemotherapeutic agents comprising an antigen binding dimer derived from an immunoglobulin covalently bound to a drug are disclosed. The dimer and drug are bound, while preserving both the antibody activity of the dimer and the pharmacological activity of the drug.

Combined treatments comprising synthetic peptide copolymers for preventing graft rejection

Compositions and methods for the treatment of graft rejection associated with transplantation of tissues and organs include combined treatment involving at least one agent selected from Copolymer 1, a copolymer 1-related heteropolymer or an ordered peptide in combination with at least one additional known immunosuppressive agent. Compositions and methods for the treatment of graft rejection using ordered peptides or ordered copolymer 1-related heteropolymers as monotherapy are also provided.

Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides

The present invention is directed to polypeptides and peptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Morever, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides or peptides to the mammal.

Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd

Compositions and methods for treating and preventing host-versus-graft disease and graft-versus-host disease comprising as active ingredient random copolymers of amino acids comprising one amino acid from at least three of the following groups: (a) lysine and arginine; (b) glutamic acid and aspartic acid; (c) alanine and glycine; and (d) tyrosine and tryptophan; with the proviso that the random copolymer is not Copolymer 1 or D-Copolymer 1 when the disease being treated is graft-versus-host disease.

Treatment of Crohn's disease with copolymer 1 and polypeptides

Vaccines for oral immunization against infecting agents

The invention relates to conjugates of an antigenic material selected from the group of a toxin, or a fragment thereof, a toxoid and/or an adherence antigen derived from an infecting agent, wherein said antigenic material is covalently bound to a physiologically acceptable inert carrier, such as silica, chemically-modified silica, aluminium silicate, kaolin or latex. The conjugates are for use in vaccines for oral immunization against infecting agents, e.g., gastrointestinal microbial infections such as cholera.

Copolymer-1 Improvements in Copolymer Mixtures

Vaccines for oral immunization against infecting agents

Combined treatments comprising synthetic peptide copolymers for preventing graft rejection

The present invention provides compositions and methods for the treatment of graft rejection associated with transplantation of tissues and organs. More specifically, the compositions and methods of the present invention relate to combined treatment involving at least one agent selected from Copolymer 1, a copolymer 1-related heteropolymer or an ordered peptide in combination with at least one additional known immunosuppressive agent. The present invention also provides compositions and methods for the treatment of graft rejection using ordered peptides or ordered copolymer 1-related heteropolymers as monotherapy.

Arzneimittel mit verzoegerter freisetzung.

An peptide polymerisationsprodukte gebundene muramyl-peptide und sie enthaltende pharmazeutische zusammensetzungen.

Platinkomplexe enthaltende antikrebsarzneimittel.

Behandlung der multiplen sklerose durch einnahme von copolymer-1

Synthetic peptides for the treatment of myasthenia gravis and compositions comprising them

Peptides having at least nine amino acid residues each including an amino acid sequence which corresponds to position p200-208 or p262-266 of the human acetylcholine receptor (alpha)-subunit, but differing therefrom by one or more amino acid substitutions, are disclosed. These peptides inhibit the proliferative response of human peripheral blood lymphocytes to the myasthogenic peptides p195-212 and p259-271 and are suitable for treatment of subjects afflicted with myasthenia gravis.

Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie

Synthetische peptide für die behandlung von myasthenia gravis

Peptidos sinteticos para el tratamiento de la miastenia gravis.

SE DESCUBREN PEPTIDOS QUE TIENEN AL MENOS NUEVE RESIDUOS AMINOACIDOS QUE INCLUYEN CADA UNO UNA SECUENCIA AMINOACIDA QUE CORRESPONDE A LA POSICION P200-208 O P262-266 DE LA SUBUNIDAD ALFA RECEPTORA DE ACETILCOLINA HUMANA, PERO QUE DIFIEREN POR UNA O MAS SUSTITUCIONES AMINOACIDAS.ESTOS PEPTIDOS INHIBEN LA RESPUESTA PROLIFERATIVA DE LIMFOCITOS PERIFERICOS DE LA SANGRE HUMANOS A LOS PEPTIDOS MIASTOGENICOS P195-21 Y P259-271 Y SON ADECUADOS PARA EL TRATAMIENTO DE SUJETOS AFECTADOS DE MIASTENIA GRAVIS.

Verbesserungen in zusammensetzungen von kopolymeren enthaltend kopolymer-1

Antibody combinations and use of same for treating cancer

A method of identifying a combination of antibodies with a combined improved anti-tumor activity is provided. The method comprising: (a) identifying binding epitopes of anti ErbB-2 antibodies; and (b) selecting a combination of at least two antibodies of the anti ErbB-2 antibodies exhibiting binding to different epitopes on the ErbB-2, at least one of the different epitopes being localized to a dimerization site of the ErbB-2, the combination of antibodies being with the combined improved anti-tumor activity. Also provided are novel antibody combinations uncovered according to the present teachings.

Synthetic peptides for the treatment of myasthenia gravis.

Peptide polymers and pharmaceutical compositions comprising them for treatment of myasthenia gravis

a BACTERIOPHAGE-PROTEIN CONJUGATE

Fillable Palm Cooling Device

A fillable palm cooling device is described. The fillable palm cooling device is configured to be filled with a cool substance, and includes at least a first endcap configured to be removed to enable the fillable tube to be filled with the cool substance. The fillable tube is configured to be held in palms of both hands of a person to cool the palms of both hands of the person when the fillable tube is filled with the cool substance.

a BACTERIOPHAGE-PROTEIN CONJUGATE

Aptamers, multimeric aptamers and uses thereof

Monomeric and multimeric aptamers are provided. Also provided are pharmaceutical compositions which comprise same and methods of using same.

COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER

An article-of-manufacture is provided. The article-of-manufacture comprises a packaging material identified for treating cancer, packaging: (i) an anti-EGFR antibody comprising the CDR sequences of anti EGFR 565 (CNCM Deposit Number I-4262); and (ii) an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L431 (CNCM Deposit Number I-4115), anti ErbB-2 L26 (CNCM Deposit Number I- 4113) or anti ErbB-2 N12 (CNCM Deposit Number I-4112), or (iii) an anti-EGFR antibody comprising the CDR sequences of anti EGFR 111 (CNCM Deposit Number I-4261); and (iv) an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L431 (CNCM Deposit Number I-4115). Also provided are pharmaceutical compositions and methods of using the above antibodies as well as other antibody combinations for the treatment of cancer.

Synthetische peptide und diese enthaltende pharmazeutische zusammensetzungen

Methoden und zusammensetzungen zur krebstherapie und zur vorhersagbarkeit der reaktionen auf diese behandlung

Pharmazeutische zusammensetzungen, die synthetische peptidcopolymerisate enthalten, zur verhütung von gvhd

Squat exercising

The present disclosure comprises methods, apparatus, components, and techniques for performing a squat exercise. Embodiments of the present disclosure may assist the user to carry out a squat with proper form to reduce the risk of injury and increase effectiveness of the exercise. Embodiments of the present disclosure comprise a forward knee-arresting surface to restrict forward movement of the user's knees in order to keep the knees in line with the user's toes. Embodiments of the present disclosure further comprise lateral knee guides. A resistive force may be applied to the lateral knee guides to increase muscle exertion while carrying out the exercise.